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Background: Antimicrobial resistance (AMR) is a growing public health threat around the world and is not well
characterized in the developing setting. Specifically, there is a lack of information regarding nasal colonization with
S. aureus and methicillin-resistant Staphylococcus aureus (MRSA) in Latin America and Peru.
Methods: This is the report of the baseline findings of a prospective cohort study followed up over 1 year at four
geographically and ecologically distinct Peruvian Air Force bases in order to determine S. aureus nasal colonization
prevalence and risk factors. Additionally, all MRSA isolates underwent molecular analysis which included pulsed-field
gel electrophoresis and determination of virulence and resistance genes.
Results: We enrolled 756 military personnel. Anterior nares colonization with Staphylococcus aureus was detected in
73 of 756 participants (9.7 %) and MRSA was detected in 2 of 756 (0.3 %). Colonization rates differed significantly
(P = 0.02) between geographic enrollment sites: Talara-4.3 %, Iquitos-9.1 %, Arequipa-14.0 % and Lima-11.3 %. Risk
factors for S. aureus colonization included being male and a reported history of respiratory disease.
Conclusion: Overall, we found low prevalence of S. aureus and MRSA nasal colonization in this Peruvian military
population. These findings contribute to the overall epidemiological understanding of S. aureus and MRSA in Latin
America. The colonization rates which varied based on geographical location warrants further study.
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The increasing prevalence of methicillin-resistant Staphylo-
coccus aureus is a global problem, affecting military and
non-military populations around the world. MRSA was first
documented in 1960, and until the late 1990s, its presence
was confined largely to hospital settings with occasional
outbreaks. Since then, the number of outbreaks and infec-
tions caused by MRSA, specifically community–associated
methicillin-resistant Staphylococcus aureus (CA-MRSA)
strains increased steadily [1, 2]. USA300 genotype is the
predominant CA-MRSA strain recovered from outbreak
investigations in U.S. and different countries in Europe and
Asia, such as Japan [3], constituting a common cause of
community associated skin and soft tissue infections
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MRSA is a risk factor for subsequent infection by these
bacteria [4, 5]. In non-Latin American populations,
colonization status varies with approximately 20–30 %
persistently colonized and 20 % is intermittently colo-
nized [6–8]. Colonization is facilitated by the anatomy of
the nasal vestibule and the resistance of S. aureus to mi-
crobicide peptides in the mucus [9]. Nasal colonization
appears to change during one’s lifetime. Colonization be-
gins shortly after birth, decreases during the first 5 years
and then it increases until 50 % are carriers between 6
and 12 years; and finally it decreases as children mature
and become adults [10]. In the military setting, Staphylo-
coccus aureus infections complicate combat-related injuries
and produce skin and soft-tissue infections during deploy-
ments or training. Among U.S. soldiers, MRSA SSTIs rep-
resent a considerable burden, and nasal colonization is a
risk factor for subsequent disease [1, 11–14]. For example,
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38 % in MRSA-colonized subjects while in non-colonized
it was only 2 % [11].
The Centers for Disease Control and Prevention’s
(CDC) 2013 report on antibiotic resistant pathogens listed
MRSA as one of the most serious threats, causing 80,461
severe infections and 11,285 deaths per year in the U.S.,
leading to a heavy burden of the healthcare system [15].
Similarly, the 2014 WHO Global Health Report on Anti-
microbial Resistance reported that in all the WHO regions,
MRSA prevalence of infections was above 20 % and in-
creased the risk of death and the associated healthcare
costs [16, 17]. In Latin America, a surveillance network for
resistant bacterial infections was organized in 1998 under
Pan American Health Organization (PAHO) sponsorship;
collecting data from specific national and regional hospitals
with adequate laboratory infrastructure and resources.
However, there is little information regarding the preva-
lence in other areas, so the geographic extent and the char-
acteristics of MRSA infections in Latin America are not
well described in terms of prevalence, isolates, and risk fac-
tors [18]. Our current knowledge indicates that four MRSA
clones are the most prevalent in Latin America: Brazilian,
Pediatric, Cordobes/Chilean and New York/Japan, with
marked differences in virulence, antimicrobial resistance
profile and geographical distribution [19].
In Peru, current information about MRSA is mostly
limited to case reports or series from hospital-based sam-
ples from reference hospitals with appropriate protocols
for lab procedures and resources. Unfortunately, these
studies do not inform us about the prevalence of S. aureus
nasal colonization nor the epidemiological characteristics
in the community, especially in young at-risk populations
such as military personnel. Our work was the first study
to systematically determine the prevalence and the mo-
lecular characteristics of nasal colonization with Staphylo-
coccus aureus and MRSA among a Peruvian military
population in multiple cities in Peru. Herein, we report
the baseline results of this study.Methods
Study design
We conducted a prospective cohort study with 1 year of
follow-up among active duty military personnel from
four bases one in each region of the Peruvian Air Force
(Lima, Arequipa, Talara, and Iquitos). This is the report
of the baseline findings of this cohort. The study population
included male and female military active duty personnel,
between age 18 and 59 years, stationed at these bases with
different climate characteristics (Iquitos is located in the
jungle; Talara, in the northern desert coast, Lima at the
central coast with mild to warm temperatures depending
on the season, and Arequipa, which is located at highaltitude in the southern highlands, with a dry and relatively
cold climate). See Fig. 1.
Study procedures
We enrolled military personnel from four large bases in
each Air Force region. After we obtained written informed
consent, each participant completed a self-administered
questionnaire about demographic and risk factors and
provided a nasal swab. Investigators obtained a sample
from the vestibular area of each of the nares, using BD
BBL CultureSwabs® (BD Diagnostic, Sparks MD). Each
nasal swab specimen was placed in a refrigerated con-
tainer and later stored in a refrigerator at 4 °C until the
time of the shipping to Naval Medical Research Unit-6 lab
(NAMRU-6). Once they arrived at NAMRU-6 Bacteri-
ology lab, the time gap between sample collection and
plating was 1 month.
Lab procedures
Labeled swabs were shipped to the Naval Medical Re-
search Unit N° 6 (NAMRU-6) located at Lima, Peru. Nasal
culture specimens were placed in 5 ml of tryptic soy broth
(TSB) supplemented with 6.5 % NaCl and incubated for
18-24 h at 35 °C. After that time, a 75 microL aliquot was
plated onto mannitol salt agar. Plates were incubated for
up to 48 h at 37 °C and inspected for yellow colonies char-
acteristic of S. aureus. Identified isolates were sub cultured
onto tryptic soy agar with 5 % sheep blood. Subsequent
colonies underwent catalase and coagulase testing per
Micro Lab Standard Operational Procedures (SOP) at
NAMRU-6. All confirmed S. aureus isolates collected
from the nasal swabs were shipped to Uniformed Ser-
vices University (USU)’s Laboratory where they under-
went susceptibility testing using disk diffusion tests for
identifying MRSA strains, following the standards estab-
lished by the Clinical and Laboratory Standards Institute
[20]. Additionally, all MRSA strains underwent pulsed field
gel electrophoresis (PFGE) procedures. Using polymerase
chain reaction (PCR) we detected Panton-Valentine Leuko-
cidin (PVL), arginine catabolic mobile element (ACME),
staphylococcal chromosome cassete (SCCmec) type, pres-
ence of toxic shock syndrome toxin (TST), gene ileS-2 for
resistant to mupirocin (mupA), and tolerance to chlorhexi-
dine (qacA/B) using standard protocols.[7].
Statistical analysis
Overall and baseline colonization status are described
based on gender, rank, base of recruitment, age group,
time of service in the Peruvian Air Force (≤10 years,
11–20 years, > 20 years), type of activities, smoking sta-
tus, previous hospitalizations in the last 12 months,
previous deployments, use of antibiotics in the last
12 months, previous SSTIs in the last 12 months, previ-
ous respiratory diseases, use of corticosteroids in the
Fig. 1 Map of Peru showing the location of the four sites. Lima, the capital city of Peru is located at the central desert coast; Talara, in the
northern desert coast; Arequipa, in the southern highlands; and Iquitos is located in the northeastern jungle (Image taken from Google Earth)
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and is reported as numbers and proportions with two-
sided 95 % confidence intervals. We also report the
prevalence rate of nasal colonization with MRSA
strains and the results of the antimicrobial susceptibil-
ity for those isolates positive to Staphylococcus aureus.
We used a logistic regression model to determine the
association with the variables listed above. The Institu-
tional Review Boards at USU (Bethesda, MD, USA),
and NAMRU-6 (Lima Peru) approved the research
protocol.
Results
Demographic and clinical characteristics
We enrolled 756 participants. The mean age of the par-
ticipants was 30.3 ± 11.5 years, but almost 60 % of our
study population was younger than 30 years. Slightlymore than 80 % were male and 61 % of the participants
had more than 10 years of military service. Almost 90 %
of the study population included Non-Commissioned
officers and troops, and their occupations included ad-
ministrative (32.5 %), instructional (36.5 % and combat
(29.2 %) activities. We found that 20.1 % of the partici-
pants had a reported medical condition. Of them, 10 %
reported gastrointestinal diseases, 5.4 % reported a skin
disease, 2.6 % reported a respiratory disease, and 1.1 %
reported an infectious disease. More than a third of the
participants (34.8 %) reported the use of antibiotics
during the previous year; of these, 52 % (136) gave a
specific antibiotic. In addition, 20.2 % reported the use
of corticosteroids; and 11.6 % of the enrolled participants
were hospitalized during the previous year. Regarding the
diagnosis of any SSTI during the previous year, only 5.8 %
reported a SSTI. Smoking was common: 34.2 % were
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reported never smoking (Table 1).
Baseline nasal colonization with Staphylococcus aureus
and MRSA
The baseline nasal colonization prevalence among the
756 enrolled participants was 9.7 %. There were two pe-
riods of recruitment, in October-November 2013 (655
participants) and April-August 2014 (101 participants),
and the baseline nasal colonization rates for each period
were similar (9.8 % vs. 8.9 %, p = 0.7853, Z-statistic for
comparison of two proportions). The overall rate of
colonization with MRSA was 0.3 % during the study
period (2 of 756). These isolates were collected during
the 6 month visit at Arequipa, one in a participant en-
rolled in October 2013 and a second from a different
participant who was enrolled in in May 2014). Molecular
analysis of these MRSA isolates demonstrated that they
possessed SCCmec type IV and qacA/B (chlorhexidine
tolerance), but lacked genes for PVL, mupirocin resist-
ance, and toxic shock syndrome toxin (TST).
Table 2 shows statistically significant associations be-
tween prevalence of nasal colonization at baseline and
demographic and clinical variables. Those participants
between 18 and 29 years old and 40 to 49 years old had
a higher prevalence of nasal colonization (10.2 % vs.
11.3 %); while, the prevalence was lower than 7 % for
other age groups. Nasal colonization was greater in male
than female (10.3 vs. 6.8 %, p = 0.201). The troops had
11.5 % of nasal baseline nasal colonization, higher than
officers or non-commissioned officers (9.5 % vs. 8.2 %).
There was a statistically significant difference in the
distribution of nasal colonization by base of recruit-
ment (p = 0.023); Talara had the lowest baseline preva-
lence (4.3 %) compared to the other three bases that
had similar rates (Iquitos-9.1 %, Arequipa-14.0 % and
Lima-11.3 %). Those who lived on base but not in the
barracks had the lowest prevalence (5.3 %) but this was
not significantly (p = 0.198) different from those who
lived at the barracks (11.2 %) and those who lived off
the base (9.9 %).
Having a respiratory disease increases the prevalence of
nasal colonization (30 %) compared with those without re-
spiratory disease (9.1 %, p = 0.002). Smoking did not affect
the prevalence of nasal colonization; the rates were similar
among those who never smoked (8.1 %), previous smokers
(12.7 %) and currently smokers (10.4 %) (p = 0.300)
(Table 3).
Among those who used antibiotics during the last year,
the nasal colonization prevalence at baseline was not dif-
ferent among those who used them (11.0 %) or not
(9.1 %). However, when we analyzed the use of dicloxa-
cillin the previous year, those who reported its use had a
33.3 % prevalence of nasal colonization, compared withthose who did not report its use (9.3 %, p = 0.005). Re-
garding the use of corticosteroids, those who used them
the previous year, had a prevalence of 12.4 %, which was
similar to those who did not use them (8.9 %), (p=: 0.432).
In terms of hospitalization during the previous year,
the rates were similar among those who were hospitalized
(10.2 %) and those who were not (9.6 %) (p = 0.971). Simi-
larly there was no difference in prevalence between those
who had the diagnosis of SSTIs during the last year
(9.1 %) and those who did not (9.5 %). The identified risk
factors for S. aureus colonization included being male and
a reported history of respiratory disease; while time of ser-
vice had a slight protective effect.
Antimicrobial susceptibility of positive isolates and
MRSA isolates
NAMRU-6 and USUHS labs processed 183 positive
Staphylococcus aureus samples from the participants
during the study period (1 year). Antimicrobial suscepti-
bility is reported in Table 3. The highest resistance was
to erythromycin (16.4 %). In addition, 6.6 % had an indu-
cible resistance to clindamycin. All isolates were susceptible
to ceftaroline, trimethoprim-sulfamethoxazole, vancomycin,
and linezolid (Table 4).
Discussion
Baseline prevalence
There are only a few studies of nasal colonization in ac-
tive duty military populations, primarily from the US
and one from China, but none in Peru or Latin America.
These studies found that the prevalence of colonization
in American recruits was 31 % [11], while the Chinese
military found a different rate depending if individuals
were deployed to urban (24.6 %) or suburban military
centers (16.1 %) [21]. In both cases, the prevalence was
higher than what we found at baseline in our study
population (9.7 %). Only two previous studies were per-
formed in community settings in Peru. One study included
only children from Cajamarca and found a prevalence of
11.9 % [22], while the second included inhabitants of an
impoverished community of Lima, and found that among
adults of different ages the prevalence of nasal colonization
ranged from 20.4 to 39.6 % [23]. These two previous stud-
ies in Peru are comparable with others studies performed
in Latin American countries that showed that the nasal
colonization rates with Staphylococcus aureus in commu-
nity settings was quite varied. In adult populations, the
nasal colonization rates in Brazil ranged between 32.7 %
[24] and 40.8 % [25]; while among Colombian medical stu-
dents the rate was 25 % [26]. The prevalence we obtained
in the Peruvian military was closer to the prevalence rate
reported among adult students in Nigeria (14 %) and
healthcare workers in Nicaragua (6.7 to 11.6 %) [27, 28]. In
Peru, 3 MRSA strains from Peruvian citizens returning





18 – 29 years 450 59.5
30 – 39 years 95 12.6
40 – 49 years 151 20.0
50 years or more 60 7.9
Time of service
10 years or less 463 61.2
11 – 20 years 103 13.6




























Inside the base 114 15.1




Number of medical conditions
None 604 79.9
Table 1 Demographic characteristics of study participants
(Continued)
One disease 118 15.6
More than one disease 34 4.5


















Past smoker 126 16.7
Current smoker 259 34.2
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and the other two were ST8 clones which are related to
the USA300 clone [29].
We found differences in the prevalence of nasal
colonization based on the site of the geographical site if
study enrollment. Of the four sites, Lima is the capital
city of Peru (approximately 10 million inhabitants), while
Arequipa (900,000 inhabitants) and Iquitos (420,000 in-
habitants) are the most important urban centers in the
highlands and the jungle and had higher prevalence
rates; while Talara, which is a smaller city than the
other three (101,000 inhabitants), had only 4.3 %. This
colonization prevalence differences may be attributed
to a number of factors including climate and ecology,
population size, or access to healthcare. An important
aspect of population size is that it generally suggests
differences in commercial movement, and therefore ac-
cess to common antibiotics that are still sold without a
medical prescription at small pharmacies and drug-
stores. Additionally, the distribution of antibiotics to
each military health facility is based on the most prevalent
diseases and the size of the base, which are larger in Lima,
Arequipa and Iquitos where administrative and oper-
ational regional offices are located, and therefore exceed
Table 2 Prevalence of baseline nasal colonization among the different variables under study (N = 756)
Variable Baseline Nasal colonization (%, 95 % CI) P value
Positive (n = 73) Negative (n = 683)
Age
18 – 29 years 10.2 (7.4 – 13.0) 89.8 (86.9 – 92.6) 0.537a
30 – 39 years 6.3 (1.4 – 11.2) 93.7 (88.8 – 98.6)
40 – 49 years 11.3 (6.2 – 16.3) 88.7 (83.7 – 93.8)
50 years or more 6.7 (0.3 – 13.0) 93.3 (86.9 – 99.7)
Time of service
10 years or less 10.6 (7.8 – 13.4) 89.4 (86.6 – 92.2) 0.334
11 – 20 years 5.8 (1.3 – 10.4) 94.2 (89.6 – 98.7)
20 years or more 9.5 (5.3 – 13.7) 90.5 (86.3 – 94.7)
Sex
Female 6.8 (2.7 – 10.9) 93.2 (89.0 – 97.3) 0.201
Male 10.3 (7.9 – 12.7) 89.7 (87.3 – 92.1)
Rank
Officers 9.5 (3.2 – 15.8) 90.5 (84.2 – 96.8) 0.340
Non-Commissioned Officers 8.2 (5.3 – 10.9) 91.8 (89.0 – 94.7)
Troops 11.5 (7.9 – 15.1) 88.5 (84.9 – 92.1)
Base of recruitment
Iquitos 9.1 (5.5 – 12.6) 90.9 (87.4 – 94.5) 0.023
Arequipa 14.0 (8.7 – 19.4) 85.9 (80.6 – 91.3)
Talara 4.3 (11.8 – 7.5) 95.7 (92.5 – 98.8)
Lima 11.3 (6.6 – 15.9) 88.7 (84.0 – 93.4)
Number of activities
Not related 10.4 (4.5 – 16.2) 89.6 (83.8 – 95.5) 0.587
Unique 9.1 (6.8 – 11.5) 90.9 (88.5 – 93.2)
Multiple 12.9 (4.9 – 20.8) 87.1 (79.2 – 95.1)
Number of medical conditions
None 9.9 (7.5 – 12.3) 90.1 (87.7 – 92.5) 0.122
One disease 6.1 (1.7 – 10.5) 93.9 (89.5 – 98.3)
More than one disease 17.6 (4.6 – 30.7) 82.4 (69.3 – 95.4)
Respiratory diseases the previous year
No 9.1 (7.0 – 11.2) 90.9 (88.8 – 92.9) 0.002
Yes 30.0 (9.4 – 50.6) 70.0 (49.4 – 90.6)
Use of antibiotics the previous year
No 9.1 (6.4 – 11.9) 90.9 (88.1 – 93.6) 0.598
Yes 11.0 (7.2 – 14.8) 88.9 (85.2 – 92.8)
Unknown 7.6 (11.3 – 14.0) 92.4 (85.9 – 98.9)
Use of dicloxacillin previous year
No 9.3 (7.2 – 11.4) 90.7 (88.6 – 92.8) 0.005
Yes 33.3 (5.4 – 61.2) 66.7 (38.8 – 94.6)
Use of corticosteroids the previous year
No 8.9 (6.5 – 11.4) 91.0 (88.6 – 93.5) 0.432
Yes 12.4 (7.2 – 17.7) 87.6 (82.3 – 92.8)
Unknown 8.9 (2.1 – 15.9) 91.0 (84.1 – 97.9)
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Table 2 Prevalence of baseline nasal colonization among the different variables under study (N = 756) (Continued)
Hospitalized during the previous year
No 9.6 (7.3 – 11.9) 90.4 (88.1 – 92.7) 0.971
Yes 10.2 (3.8 – 16.6) 89.8 (83.4 – 96.2)
Unknown 8.7 (0.0 – 20.5) 91.2 (79.5 – 100)
Diagnosis of SSTIs during the previous year
No 9.5 (7.3 – 11.8) 90.5 (88.2 – 92.7) 0.848
Yes 9.1 (0.5 – 17.7) 90.9 (82.3 – 99.5)
Unknown 12.2 (5.2 – 22.4) 87.8 (77.6 – 97.9)
Smoking status
Never 8.1 (5.2 – 11.0) 91.9 (88.9 – 94.8) 0.297
Past smoker 12.7 (6.9 – 18.5) 87.3 (81.5 – 93.1)
Current smoker 10.4 (6.7 – 14.2) 89.6 (85.8 – 93.3)
Place of residence
Barracks 11.2 (7.3 – 15.1) 88.8 (84.9 – 92.7) 0.198
Inside the base 5.3 (1.1. – 9.4) 94.7 (90.6 – 98.9)
Outside the base 9.9 (6.9 – 12.9) 90.1 (87.1 – 93.0)
aWe used the Fisher’s exact test. For the rest of the variables, we used the Pearson chi square test
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ational base. The increased exposure to antibiotics in
Lima, Iquitos and Arequipa might favor the development
of nasal colonization with Staphylococcus aureus by elim-
inating other commensal bacteria colonizing the human
nares; unfortunately information regarding the most used
antibiotics at each of the bases or local areas is currently
unavailable.
Dicloxacillin is an antibiotic belonging to the beta lac-
tam family that is used extensively for the treatment of
SSTIs. We had expected that the use of dicloxacillin might
reduce the rates of nasal colonization with Staphylococcus
aureus, but we found the opposite. Possibly, the normal
microbiota in the anterior nares is more susceptible than
Staphylococcus aureus to dicloxacillin, therefore favoring
the Staphylococcus aureus growth. Another possible
reason can be the misuse of this antibiotic, which is
usually prescribed for 7 to 14 days, but if the dose and
time of prescription were not adequate, the antibiotic
might have limited effect. We were not able to collect
information regarding the dose, time of prescription,
where the antibiotics were purchased, or if the treat-
ment was completed.
We identified only two participants with MRSA and
therefore our overall prevalence of MRSA colonization
during the study period was 0.3 % (2 of 756). These isolates
possessed SCCmec type IV which is the characteristic mo-
bile genetic element carrying the mecA gene (methicillin-
resistance) found most commonly in CA-MRSA strains.
Our MRSA colonization prevalence was close to thosereported in previous studies in Peru and Latin America,
where it ranges from 0.6 to 1.8 % [23, 30, 31] in communi-
ties; however these proportions are lower than those ob-
served in developed countries like US or Europe. In
terms of military populations, our results reflect that
MRSA nasal colonization is lower than rates reported
in US military populations (3 %), while the Chinese
study did not detect any MRSA [11, 21].
Our questionnaire was not designed to provide more
specific historical information regarding the type of SSTI
and treatments prescribed, dose and timing of antibiotics
and corticosteroids, time of hospitalization, place, and
antibiotics used during this time, which could have given
us more detailed information regarding these risk factors.
Also, given that this was a self-administered questionnaire,
there is the potential for recall bias. In addition, it is pos-
sible that some participants did not understand the ques-
tions asked or did not know the medical terms used;
therefore they left the questions blank. In addition, it is
possible that sample handling could have affected the re-
covery of positive S. aureus isolates, specifically during the
sampling procedure due to discomfort of the participants
that led to movements of the head and a poor quality
sample, and the limited available timeframe we had for
doing it. Different climate conditions at each site may have
affected also the recovery due to the use of a refrigerated
container that could not have kept a low temperature at
all times.
We believe our results can serve as a proxy to under-
standing of the nasal colonization with Staphylococcus
Table 3 Potential risk factors associated with baseline nasal






Use of antibiotics during
the previous year
No 400 Ref Ref
Yes 238 1.2 1.4 (0.8 – 2.6) 0.283
Hospitalization during
the previous year
No 566 Ref Ref
Yes 72 1.0 1.0 (0.4 – 2.4) 0.980
Diagnosis of SSTI
during the previous year
No 600 Ref Ref
Yes 38 0.5 0.4 (0.1 – 1.8) 0.237
Sex
Female 122 Ref Ref
Male 516 1.8 2.4 (1.0 – 5.7) 0.043
Base of recruitment
Talara 144 Ref Ref
Iquitos 207 2.5 2.5 (0.9 – 6.5) 0.065
Lima 149 2.8 2.7 (0.9 – 7.3) 0.051
Arequipa 138 3.9 4.5 (1.7 – 11.9) 0.002
Smoking status
Never smoked 312 Ref Ref
Past smoker 107 1.7 1.6 (0.8 – 3.5) 0.204
Current smoker 219 1.2 1.1 (0.6 – 2.1) 0.756
Respiratory diseases
No 619 Ref Ref
Yes 19 3.5 4.5 (1.4 – 14.7) 0.014
Time of service 638 0.99 0.97 (0.94 – 0.99) 0.030
Table 4 Antimicrobial susceptibility of 183 Staphylococcus aureus
isolates
Antibiotic Number (%) of samples
Susceptible Resistant Intermediate
Clindamycina 179 (97.8) 4 (2.2) -
Erythromycin 153 (83.6) 30 (16.4) -
Doxycycline 180 (98.4) - 3 (1.6)
Linezolid 183 (100) - -
Oxacillin 181 (98.9) 2 (1.1) -
Rifampin 183 (100) - -
TMP-SMX b 183 (100) - -
Vancomycin 183 (100) - -
Gentamicin 177 (96.7) 6 (3.3) -
Levofloxacin 182 (99.5) 1 (0.5) -
Ceftaroline 183 (100) - -
a 6.6 % of the samples showed inducible resistance to clindamycin
bTMP-SMX, trimethoprim-sulfamethoxazole
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have a remarkable antimicrobial susceptibility with very
little resistance when compared with other populations.
This susceptibility may allow us an optimization of the
current treatment of different infections where
Staphylococcus aureus is a common etiologic agent.
This standardization should help to reduce the indis-
criminate exposure to more expensive and broader
spectrum antibiotics that should be left as second or
third line options, which are more expensive and in-
crease the risk of adverse reactions.
Conclusions
In summary, we found a low prevalence of baseline nasal
colonization with Staphylococcus aureus (9.7 %) and
MRSA (0.3 %) in an active duty military population inPeru. Our results increase the current knowledge about
Staphylococcus aureus nasal colonization in Peru and
Latin America. Further study exploring the geographic-
ally differences in S. aureus nasal colonization warrants
further investigation.Abbreviations
AMR, Antimicrobial resistance; MRSA, methicillin-resistant Staphylococcus aureus;
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